← board
ENVB
distress 4/10 · elevated risk$1.33-1%today-92% from 52w high
Lead: neuropsychiatric disorders
Revenue
pre-revenue
Liquidity
$0M
Runway
—
Shares 1y
+13%
Price & events
-68.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.7%
1D
-2.2%
1W
-1.5%
1M
-66.9%
3M
-68.6%
6M
-91.9%
1Y
-99.9%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $4.90M
- Volume
- 7.13K
- 52 Week Range
- $1.27 – $17.40
- Total Shares
- 3.68M
- Float Shares
- 3.54M
- Short %
- 0.39%
- % Held by Insiders
- 10.81%
- % Held by Institutions
- 2.78%
- RVOL
- 0.04x
- Beta
- 1.14
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- 2026Guided 40%trial initiationsecondaryPhase 1EB-003 · First-in-human clinical trialSEC 8-K
- 2025-03-04fda agreementReceived notice of regained compliance with Nasdaq bid price rule.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-03-06HC Wainwright & Co.Buy
Competitors — neuropsychiatric disorders
- NMRANeumora Therapeutics, Inc.$281M · D5
Recent news
- 2026-07-16Enveric Biosciences Inc (ENVB:UW): Stock Price, Quote and News - BNN Bloomberg
- 2026-07-14Price to sales forward of Enveric Biosciences, Inc. – NASDAQ:ENVB - TradingView
- 2026-07-08Enterprise value to EBIT forward of Enveric Biosciences, Inc. – NASDAQ:ENVB - TradingView
- 2026-06-29Enveric CEO to discuss EB-003 at Boston neuropsychiatry summit - Stock Titan
- 2026-06-19Enveric Biosciences Inc (ENVB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
- 2026-06-12ENVB Q4 2024 Earnings: Deep EPS Miss Reflects Clinical-Stage Challenges - Quarterly Financial Update - dars.gov.et
- 2026-06-09Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day - Investing News Network
- 2026-06-09Enveric Biosciences posts investor presentation on website under Regulation FD - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.